Browsing by Author "Uslar, Thomas"
Now showing 1 - 8 of 8
Results Per Page
Sort Options
- ItemClinical Presentation and Perioperative Management of Pheochromocytomas and Paragangliomas: A 4-Decade Experience(ENDOCRINE SOC, 2021) Uslar, Thomas; San Francisco, Ignacio F.; Olmos, Roberto; Macchiavelo, Stefano; Zuniga, Alvaro; Rojas, Pablo; Garrido, Marcelo; Huete, Alvaro; Mendez, Gonzalo P.; Cortinez, Ignacio; Zemelman, Jose Tomas; Cifuentes, Joaquin; Castro, Fernando; Olivari, Daniela; Dominguez, Jose Miguel; Arteaga, Eugenio; Fardella, Carlos E.; Valdes, Gloria; Tagle, Rodrigo; Baudrand, RenePurpose: Latin American reports on pheochromocytomas and paragangliomas (PPGLs) are scarce. Recent studies demonstrate changes in clinical presentation and management of these patients. Herein, we assessed the main characteristics of PPGL patients in our academic center over the past 4 decades.
- ItemDiseño e implementación de un modelo de enseñanza en ambiente simulado de paracentesis abdominal(2017) Uslar, Thomas; Pizarro Rojas, Margarita Alicia; Villagrán Gutiérrez, Ignacio Andrés; Chahuan, Javier; Caro Pinto, Iván; Marziano, Gianpiero; Irribarra, María Ignacia; Uribe, Javier; Ruz Ruz, Cristian Daniel; Villafranca, Carlos; Godoy, Camila; Ordenes, María Jesús; Orus,Cristian; Rodríguez, Sebastián; Roble, Javier
- Item¿Es el cierre percutáneo de la orejuela de la aurícula izquierda comparable al tratamiento anticoagulante en fibrilación auricular?(2015) Uslar, Thomas; Anabalón, Jaime
- ItemGenetic testing for indeterminate thyroid cytology: review and meta-analysis.(2018) Vargas Salas, Sergio; Martinez, Jose R.; Urra, Soledad; Domínguez Ruiz-Tagle, José Miguel; Mena, Natalia; Uslar, Thomas; Lagos Lucero, Marcela; Henríquez Henríquez, Marcela Patricia; González Díaz, Hernán
- ItemPerspective review: lessons from successful clinical trials and real-world studies of systemic therapy for metastatic pheochromocytomas and paragangliomas(SAGE PUBLICATIONS LTD, 2024) Jimenez, Camilo; Baudrand, Rene; Uslar, Thomas; Bulzico, DanielPheochromocytomas and paragangliomas (PPGLs) are orphan tumors with the potential to spread to distant organs such as the lymph nodes, the skeleton, the lungs, and the liver. These metastatic tumors exhibit high rates of morbidity and mortality due to their frequently large tumor burden, the progression of the disease, and the excessive secretion of catecholamines that lead to cardiovascular disease and gastrointestinal dysmotility. Several molecular drivers responsible for the development of PPGLs have been described over the last 30 years. Although therapeutic options are limited, substantial progress has been made in the recognition of effective systemic therapies for these tumors. Successful clinical trials with radiopharmaceuticals such as high-specific-activity meta-iodobenzylguanidine and tyrosine kinase inhibitors such as cabozantinib and sunitinib have been recently published. This review will discuss the results of these studies and their impact on current clinical practices. In addition, this review will provide valuable information on how to design clinical trials to treat patients with metastatic PPGLs with novel medications.
- ItemReal-world outcomes of Finerenone in Primary Aldosteronism(2025) Uslar, Thomas; Sanfuentes, Benjamín; Muñoz, Iván; Anand Vaidya; Baudrand Biggs, RenéPrimary aldosteronism (PA) treatment with mineralocorticoid receptor antagonists (MRAs) is effective but limited by side-effects and low potency of currently available options. Finerenone, a novel MRA, has emerged as a promising alternative but data in PA are lacking. This report presents a real-world study wherein PA patients on eplerenone were forced to switch to finerenone therapy during a national shortage. During treatment with finerenone, blood pressure and antihypertensive dose remained unchanged, but the proportion of patients with normal blood pressure and complete biochemical response was decreased (P = .004 and P = .008, respectively). The latter was determined by a reduction in direct renin concentration, a biomarker previously associated with increased cardiovascular risk in PA. Although these results could be explained by finerenone's unique pharmacokinetics and mechanism of action, further studies are needed to evaluate longitudinal outcomes associated with these findings and determine its effectiveness in PA treatment.
- ItemSARCOID-LIKE GRANULOMATOUS MYOSITIS-ASSOCIATED HYPERCALCEMIA. AN INFREQUENT CASE TO CONSIDER(2021) Uslar, Thomas; Olmos, Roberto; Godoy-Santin, Jaime; Mellado, Patricio; Gonzalez, GilbertoPTH-independent hypercalcemia due to granulomatous disease is well-documented and sarcoidosis is the most characteristic disease, although there are others. We describe a case of sarcoid-like granulomatous myositis. An 87-year-old man was referred with tetraparesis and hypercalcemia (albumin-corrected calcium of 13.4 mg/dl) following a trip to the Caribbean. The evaluation showed a suppressed PTH, 25-hydroxy vitamin D of 7.5 ng/ml, F-18-FDG PET/CT showed markedly increased uptake in intercostal, back, shoulder, buttock and thigh muscles and a deltoid biopsy confirmed extensive granulomatous myositis. He was prescribed glucocorticoids which resulted in normalized plasma calcium levels and complete recovery from tetraparesis. Sarcoid-like granulomatous myositis should be incorporated into the differential diagnosis of PTH-independent hypercalcemia, especially in the absence of clinical features of sarcoidosis and with special emphasis on the use of F-18-FDG PET/CT to ensure a correct approach.
- ItemUndergraduate student's perception of clinical simulation workshops: assessment of an instrument(2018) Villagran, Ignacio; Tejos, Rodrigo; Chahuan, Javier; Uslar, Thomas; Pizarro Rojas, Margarita Alicia; Varas, Julian; Achurra Tirado, Pablo; Leiva Rodríguez, Isabel; Nazar Jara, Claudio; Sirhan Nahum, Marisol; Uribe, Javier; Ruz Ruz, Cristian Daniel; Villafranca, Carlos; Soza, Romina; Solis, Na